Kymera Therapeutics KYMR Total debt

Total debt at other companies

PfizerPFE

$64.43B+4.9%

Johnson & JohnsonJNJ

$49.04B-3.4%

Regeneron PharmaceuticalsREGN

$2.71B+0.1%

Nurix Therapeutics, Inc.NRIX

$58.14M+12.0%

ArvinasARVN

$8.6M-19.6%

Monte Rosa Therapeutics, Inc.GLUE

$37.99M-7.6%

FAQ

What is Kymera Therapeutics's total debt?

Kymera Therapeutics (KYMR) reported total debt of $80.14M in Q2 2026.

How has Kymera Therapeutics's total debt changed year-over-year?

Kymera Therapeutics's total debt decreased by 8.5% year-over-year, from $87.61M to $80.14M.

What is the long-term trend for Kymera Therapeutics's total debt?

Over 5 years (2020 to 2025), Kymera Therapeutics's total debt has grown at a 35.1% compound annual growth rate (CAGR), from $18.68M to $84.07M.

What does total debt mean?

Total debt represents the aggregate sum of all interest-bearing financial obligations, including short-term borrowings, the current portion of long-term debt, and long-term debt instruments. It also encompasses capitalized lease liabilities and other debt-like financing arrangements that require fixed repayment schedules. This metric serves as a comprehensive indicator of a company's total financial leverage and its reliance on external capital providers.